Digital PCR Market Size
The global Digital PCR Market size was valued at USD 0.72 Billion in 2025 and is estimated to reach USD 1.45 Billion by 2033, exhibiting a CAGR of 7.4 % during the forecast period (2026-2033).
The end-point PCR technique, digital PCR, is utilized for accurate quantification and studying small sequences compared to related large sequences. PCR stands for a polymerase chain reaction. It amplifies the DNA or RNA segments multiple times. Finds genetic changes or infections in any individual.
Digital PCR Market Summary
| Metrics | Details |
| Market CAGR | 7.4% |
| Segments Covered | By Technology, By Product Type, By Application, By End-Users, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Digital PCR Market Dynamics
The global digital PCR market will expand due to several factors. Some of them are rising technological advancements, novel product launches, growing infectious disease incidents, and a surge in R&D activities by biopharma companies.
The increase in technological advancements and research & development by various biopharmaceutical companies is expected to drive market growth.
The surge in research and development activities by various major key players is a major factor in driving the market. PCR diagnoses various illnesses, such as infectious diseases and genetic changes. It can diagnose the disease in its earliest stage, and even if only minute amounts of antibodies or cancer cells are present, it can detect it by amplifying the DNA or RNA multiple times. Nucleic acid measurement is accurate and sensitive, thanks to digital PCR (dPCR). Traditional PCR uses agarose gel electrophoresis to detect the amplified product, making it a semi-quantitative end-point examination. The three main subtypes of digital PCR (dPCR) are beaming, droplet, and chip-based digital PCR.
One of the significant possibilities in the worldwide PCR market is the growth of R&D spending for d-PCR molecular diagnostics. To facilitate effective diagnosis, several biotechnologies and life sciences, businesses are collaborating on developing diagnostic tests and the therapeutic use of d-PCR in several illness indications to provide effective treatment.
Introducing new products by major companies and technological breakthroughs in PCR technologies fuel the market's expansion. For instance, some market participants have created unique d-PCR products that can recognize various diseases or detect various genetic abnormalities. For instance, in Mar 2021, Thermo Fisher announced United States Food and Drug Administration had completed the listing for QuantStudio 5, a real-time PCR and launched it in the market. It helps labs and developers fulfill the demands of testing.
Major key players develop the latest products or models with novel technological innovations and advancements. Most of the products receiving approval are driving the market's growth. For instance, in 2020, Thermo Fisher created several PCR kits and tests for diagnostic and research to fight the COVID-19 outbreak. They released AcroMetrix Coronavirus 2019 (COVID-19) RNA Control after receiving the US FDA's emergency use authorization (EUA) for the SARS CoV 2 multiplex real-time PCR test.
Technical limitations associated with the market are expected to hamper the market growth.
Costly equipment and PCR's technological limitations are predicted to impede market expansion. A classic d-PCR method is accompanied by a variety of technical limitations, including the need for assay procedure optimization and validation, the measurement of signals all through the exponential growth phase of the PCR amplification, difficulties in target detection caused by the existence of reaction modulators, and the inability to identify biomolecules due to the poor efficiency of the DNA sequence template. Additionally, the usage of carcinogenic chemicals, chemical binding of d-PCR reagent to dsDNA and inability to evaluate DNA quality are some of the procedural restrictions that prevent using these reagents in genomic research.
Digital PCR Market Segment Analysis
The droplet digital PCR segment is expected to hold the largest market share in the global digital PCR market.
The technology segment is further sub-segmented into digital droplet PCR, beaming digital PCR and chip-based digital PCR. Digital droplet PCR is expected to hold the largest market share due to the increasing number of product launches and various novel technological advances. Nucleic acid analysis can be done with extreme sensitivity, accuracy and exactness because of the development of digital PCR. It is also helpful for monitoring low-abundance targets, allelic variations (SNPs), targets with complicated backgrounds, and tiny changes in target levels that real-time PCR cannot pick up on. The use of this technology in in-vitro testing has now been authorized.
The droplet digital PCR divides the sample of DNA into 20,000 droplets using water-emulsion droplet technology. Every particular droplet then experiences PCR replication of the template and quantifying the positive droplets provides accurate target estimation. Absolute quantification, high precision and high sensitivity can be seen in droplet digital PCR so that it will be more helpful and accurate for analysis. For instance, in 2020, Bio-Rad announced that the droplet digital PCR SARS-CoV-2 test kit got emergency use permission from the United States Food and Drug Administration for COVID testing.
Digital PCR Market Geographical Share
The North American region holds the largest market share in the global digital PCR market.
In 2021 North America reserve an extensive share in the digital PCR market, and it is estimated that it is also going to overshadow the global market in the coming years owing to the upsurge in widespread presence of chronic diseases, the existence of key players for the progress of digital PCR devices, and prevalent foundation and substructure in the region. The growing technological advancement for developing digital PCR products shall stimulate the market. Favorable reimbursement policies and better healthcare facilities shall fuel market growth.
Most of the key players in this region are Thermo Fisher Scientific, Bio-Rad Laboratories Inc., Becton, Dickinson and Company and F. Hoffmann-La Roche, Ltd. All of them are launching various innovative and novel products. Various acquisitions and merges are also taking place, fueling the market’s growth in this region and making North America the largest shareholder.
Digital PCR Market Competitive Landscape:
The global digital PCR market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Thermo Fisher Scientific, Bio-Rad Laboratories Inc., and F. Hoffmann-La Roche, Ltd. are the three key players operating in the global digital PCR market. Other well-known players are Agilent Technologies, Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, Eppendorf, Merck, Promega Corporation, Takara Bio, Enzo Life Sciences, Meridian Bioscience, Bioneer, QIAGEN N.V, ELITech Group, Genetron Holdings Limited.
The companies are entering into collaborations, strategic partnerships, acquisitions and mergers to increase the demand for digital PCR and their global expansion. Companies are also using new product launches, product development, market expansion and technical advancement strategies to hold their market position.
Recent Developments:
- On March 5, 2026, Thermo Fisher Scientific announced advancements in its digital PCR platform portfolio, focusing on enhanced sensitivity and automation for clinical diagnostics and oncology research. The development supports the growing adoption of liquid biopsy and precision medicine applications, where highly accurate nucleic acid quantification is critical.
- On January 22, 2026, Bio-Rad Laboratories expanded its droplet digital PCR (ddPCR) systems with improved multiplexing capabilities, enabling simultaneous detection of multiple genetic targets. The innovation aims to strengthen applications in infectious disease detection and genetic mutation analysis, aligning with rising demand for high-throughput and ultra-sensitive diagnostic tools.
- On November 14, 2025, Danaher Corporation strengthened its molecular diagnostics segment through strategic portfolio expansion and integration of digital PCR technologies across its subsidiaries. This move enhances its competitive positioning in genomics and clinical diagnostics markets, reflecting increasing consolidation in the PCR ecosystem.
- On September 9, 2025, QIAGEN N.V. enhanced its QIAcuity digital PCR platform by increasing multiplexing capacity and expanding assay capabilities for infectious disease and oncology testing. The upgrade improves workflow efficiency and supports broader adoption in research and clinical laboratories.
- On July 28, 2025, Standard BioTools Inc. (formerly Fluidigm) focused on integrating advanced microfluidic technologies into digital PCR systems to improve throughput and scalability. The initiative supports expanding use cases in genomics, drug discovery, and biomarker research.
- On May 16, 2025, F. Hoffmann-La Roche Ltd. invested in next-generation PCR and digital diagnostics platforms aimed at improving early disease detection and personalized treatment approaches. The strategy aligns with increasing demand for precision diagnostics and molecular testing solutions.
- On March 3, 2025, Stilla Technologies expanded its commercial footprint through strategic partnerships and distribution agreements in North America and Asia-Pacific, enhancing accessibility of its digital PCR solutions for research and clinical laboratories.
- On February 11, 2025, Merck KGaA (MilliporeSigma) strengthened its molecular biology portfolio through collaborations and investments in PCR and digital PCR workflows, focusing on improving reagent quality and assay reproducibility.
Global Digital PCR Market – Key Companies to Watch
Thermo Fisher Scientific:
Overview: Thermo Fisher Scientific is a healthcare distributor company that serves science. They manufacture and market reagents, scientific instruments & equipment, consumables and software services. It was established in 1956 and is based in Waltham, Massachusetts, United States.
Product Portfolio:
QuantStudio 6 and 7 Pro Real-Time PCR Systems- These are PCR systems that are very flexible as they reinforce various kinds of applications and favorable conditions. The smartness of these systems is created to minimize contamination by making them run hands-free. Mobile phones can be used to schedule and even monitor the run. The QuantStudio 6 and 7 Pro systems contain 96-well blocks that comprise a technology known as VeriFlex that is used for specific temperature control. All these blocks are prorated into secluded zones, due to which there are separate cycling surrounding inside the one and same run that is ideal for optimization.
The digital PCR market report would provide access to an approx. 45+market data table, 40+figures and 180pages.
